A look at efforts to develop brain-computer interfaces, including Musk's Neuralink and a DARPA program to build a 64,000-electrode array for brain implants
Context & Ripple Effects
Four years after Elon Musk launched Neuralink to build 'direct cortical interface' implants (the 2017 founding), the field this piece surveys has split into two tracks: Musk's company, which put $158M behind a promise of human trials and showed readings from a pig's brain via a coin-shaped device under the skull (the August 2020 prototype), and DARPA's government-funded push for a 64,000-electrode array that out-scales anything the startups have demonstrated.
The reason the survey matters now is momentum: follow-on reporting shows the number of people carrying brain implants is set to double within twelve months (the 2025 tally of BCI startups), turning what was a research curiosity into a small but growing patient population.
First-order effects
- DARPA's 64,000-electrode target sets a density benchmark that Neuralink and rival BCI startups must match or explain away, since electrode count is the clearest proxy for how much signal an implant can read.
- Neuralink's pig-demo-to-human-trial pipeline is under scrutiny against its own timeline — the company said in 2019 it hoped to test on humans by Q2 2020, so each new entrant raises the bar for what counts as progress.
Second-order effects
- A doubling implant population pulls in adjacent players: surgical teams, implant hardware suppliers, and regulators now face a recurring review workload rather than one-off experimental approvals.
- Competing funders change the economics — DARPA's program gives academic labs an alternative to venture-backed startups like Neuralink, weakening any single company's claim to be the field's indispensable platform.
Third-order effects
- If both tracks hold, brain-computer interfaces consolidate around two durable structures — defense-funded research arrays and consumer-ambition startups — with the relationship between them (shared talent, shared standards, shared patients) becoming the field's defining question.
- As implant recipients multiply, the unresolved issues the survey only gestures at — long-term safety, data ownership over neural signals, reimbursement — shift from ethics-panel topics into regulatory and insurance policy.
The trend: Brain-computer interfaces are crossing from single-patient demos toward a scaling implanted population, with DARPA's electrode-density ambitions and Musk-funded startups racing on parallel tracks.